

DORSET MEDICINES ADVISORY GROUP

Recommendation Summary



**Dorset
Clinical Commissioning Group**

The Dorset Medicines Advisory Group (DMAG) includes representatives from the four provider Trusts, Public Health Dorset and GPs within the Clinical Commissioning Group (CCG). It advises the system on prescribing and commissioning of medicines in Dorset.

Summary of recommendations made by the group 10th November 2020. Formulary entries and associated documents can be accessed at www.dorsetformulary.nhs.uk.

PRODUCT	DECISION		COMMENTS
1. Products re-categorised	Previous position	Recommended position	
Potassium Chloride	Both Amber & Green	Amber	Also, with the removal of self-care medication
Nystatin pessaries	Non-formulary	Red	
Oral neostigmine	Amber	Non-formulary	Chapter 10 of the formulary
Glycopyrronium	Red	Amber	In line with NICE NG71 for sialorrhoea
Cannabis Extract Oromucosal Spray (Sativex®)	non-formulary ("Black")	Amber with SCG	For patients with MS who have not responded to alternative anti-spasticity medications in accordance with NICE NG144
2. New requests			
Naldemedine (Rizmoic®)	Green		In accordance with NICE TA 651 for treating opioid -induced constipation and locally agreed pathway for the management of constipation
Melolite Dressing	Green		Previously omitted from chapter A5-01-01

PRODUCT	DECISION	COMMENTS
Lisdexamfetamine (Elvanse®)	Amber with SCG	Lisdexamfetamine was already included in current shared care guidelines for paediatric use and had NICE NG87 support, the group approved Lisdexamfetamine to be made Amber on formulary with shared care agreements for adults with ADHD
Buprenorphine prolonged-release solution for injection (Buvidal®)	Red	The addition of Buvidal® to the Dorset formulary is to support the commissioned use of the product in Dorset. Prescribed and administered within the specialist AWP service.
Dupilumab	Non-formulary (Chapter 12)	for treating chronic rhinosinusitis with nasal polyps NICE TA648 (terminated appraisal)
3. Products considered by NICE		
NICE TA651: Naldemedine for treating opioid-induced constipation NICE TA659: Galcanezumab for preventing migraine – considered as the FAD, TA published 18 th Nov 20		
4. Miscellaneous recommendations by DMAG		
All H2 receptor antagonists (Cimetidine, Famotidine & Nizatidine)	Approved the additional wording to be added to the formulary entry	‘During the shortage of ranitidine, you can supply cimetidine, nizatidine or famotidine as a last resort’.
myCOPD statement to be added to the COPD section	Approved the statement to be added to chapter 03.01	The myCOPD app is being rolled out locally for both patients and healthcare professionals (primary and secondary care) to support co-management of COPD. Within the app there is education, online exercise programmes, risk factor modification and medicines support, including inhaler technique training’
Codeine Linctus	approved the removal of linctus and self-care medicine symbol from the codeine phosphate entry 04.07.02 for clarity.	
Botulinum toxin (Xeomin®)	Addition to the Guideline for the Pharmacological management of Parkinson’s Disease as RED	in accordance with NICE TA605

PRODUCT	DECISION	COMMENTS
NICE MIB220 Prontosan For Acute and Chronic wounds briefing link	To be added to the prontosan formulary entry	The briefing supports the use of prontosan as an alternative to saline or water to cleanse wounds during dressing changes
5. Further Assessment / Evidence Required		
6. New documents approved		
<ul style="list-style-type: none"> • The Thickening Quantities per Month Guidance • Mesalazine In Focus • The Mesalazine Patient Switch Letter • The Commissioning Statement for Naldemedine and Naloxegol • Shared Care Guideline for Delta-9-Tetrahydrocannabinol Combined with Cannabidiol (THC:CBD – Sativex®) • Dorset Pathway for the use of Sativex® for Spasticity in MS • Pathway for the use of Sativex® in Multiple Sclerosis • Paediatric liquids & Suspension Guidance 		
7. Documents Reviewed		
<ul style="list-style-type: none"> • Insulin in Type 2 Diabetes Guidance • Commissioning Statement on the use of Growth Hormone for Children and Adults • The faecal Calprotectin Pathway • The Constipation Guidance • PAN Dorset Wound Care formulary Pathway • Skin barrier and Wound Care Products Request Form • Prescribing Guideline for Parkinson’s Disease • Shared Care Guideline for Prescribing Dopamine Agonists in Parkinson’s Disease • Shared care guideline for Selegiline and Rasagiline in Parkinson’s Disease • Shared Care Guideline for Entacapone (including in combination) or Opicapone in Parkinson’s Disease • Shared Care Guideline for Amantadine in Parkinson’s Disease 		

Classification of products:

'RED' drugs for hospital use only

'AMBER with shared care' drugs suitable for use on specialist advice with shared care arrangements

'AMBER' drugs suitable for use on specialist advice without shared care arrangements

'GREEN' drugs suitable for prescribing in primary and secondary care

'Not Recommended' – drugs not recommended for use in Dorset